Invitrogen's plan to spend half a billion dollars on acquisitions in 2006 remains on track, Chairman and CEO Greg Lucier said during a conference call last week, despite what he views as higher premiums being paid for acquisition targets.

Lucier also said during the call, which followed the release of Invitrogen's first-quarter results, that the firm believes the BioReliance business, which has struggled over the last year, will recover and return to positive sales growth this year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.